Intensity Therapeutics, INC 8-K filings

Intensity Therapeutics has entered into an agreement to potentially sell up to $15 million of its common stock through an at-the-market offering.

Intensity Therapeutics has removed James Ahlers as an officer, transitioning him to a senior corporate finance consulting role, effective May 21, 2024.

Intensity Therapeutics has appointed Thomas Dubin to its Board of Directors, increasing the board size to five members and regaining compliance with Nasdaq audit committee requirements.

Intensity Therapeutics has partnered with The Swiss Group for Cancer Research SAKK to conduct a Phase 2 clinical trial of INT230-6 in women with triple negative breast cancer in Europe.

Intensity Therapeutics announced its first quarter 2024 financial results and provided a corporate update, highlighting progress in its clinical programs and financial runway.

Intensity Therapeutics received a notice from Nasdaq for not meeting audit committee composition requirements after a board member resigned from the committee.

Intensity Therapeutics announced its full year 2023 financial results and provided a corporate update, highlighting progress with its lead drug candidate, INT230-6, and upcoming clinical milestones.

Intensity Therapeutics has adopted a new incentive compensation plan, effective retroactively from October 1, 2023, designed to reward employees based on individual and company performance.